COVID-19 UNLOCKING INDIA’S CAPACITY IN LIFE SCIENCES Today, for India, the COVID-19 pandemic is a strong catalyst to re-inforce the Make in India initiative to facilitate investment, promote innovation, enhance skill development, protect intellectual property and build best in class manufacturing infrastructure in the life sciences sector. For fostering an innovation ecosystem or hub within India, interventions across three dimensions will be required which includes encouraging industryacademia collaboration; increasing R&D investment; and reinvigorating government support
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc